Filana Therapeutics (FLNA) Current Assets (2010 - 2026)

Filana Therapeutics has reported Current Assets for 17 years, with the latest figure at $83.7 million in Q2 2026.

• On a quarterly basis, Current Assets fell 27.08% year-over-year to $83.7 million in Q2 2026; TTM through Jun 2026 was $83.7 million, a 27.08% decrease from a year earlier, with the FY2025 full-year figure at $97.7 million, down 28.44% from the prior year.
• Current Assets was $83.7 million for Q2 2026 at Filana Therapeutics, down from $88.0 million in the prior quarter.
• The five-year high for Current Assets was $222.2 million in Q1 2022, with the low at $83.7 million in Q2 2026.
• Average Current Assets over 5 years is $154.4 million, with a median of $143.4 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Current Assets surged 34.87% in 2024, then slumped 48.31% in 2025.
• Over 5 years, Current Assets stood at $211.2 million in 2022, then tumbled by 38.63% to $129.6 million in 2023, then climbed by 5.32% to $136.5 million in 2024, then decreased by 28.44% to $97.7 million in 2025, then decreased by 14.31% to $83.7 million in 2026.
• The last three Current Assets figures came in at $83.7 million (Q2 2026), $88.0 million (Q1 2026), and $97.7 million (Q4 2025), per Business Quant data.